_p.png){kind=logo}
INVESTOR RELATIONS
(TSXV:VPT, OTC:VPTDF)
Ventripoint Diagnostics Ltd is a medical device company that is primarily engaged in the development and commercialization of cardiac diagnostic tools. It sells its products worldwide.
CAPITAL STRUCTURE
Shares Outstanding 155M
Shares Fully Diluted 178M
Recent Share Price CDN$.53 (US$.42)
52-Week Range CDN$.07-.68
Market Cap ca. CDN$90M (USD$70M)
Debt None
Cash $10M
Liquidity CDN$1.0M/day
USD$0.75M/day
Symbol: TSX-V: VPT & OTC: VPTDF
OUR STRATEGY
Staying true to our story, Ventripoint Diagnostics Ltd. continues to be dedicated to developing quality, smart tools that help solve the immediate needs of our healthcare clinicians, and most importantly improves the clinical experience for our youngest to oldest patient.
Ventripoint has entered into a collaboration with the Veterinary Hospital at the North Carolina State University (NCSU) to test and evaluate the use of the VMS+ in echocardiography of canines with the goal of expanding this technology to all animals.
VMS+ could eventually help treat our most loyal best friend.
EXPLORING NEW FRONTIERS FOR VMS+
Read More
LATEST FINANCIAL DATA
Quarterly Reports
Annual Reports
LATEST PRESS RELEASES
LATEST EVENTS
AUG
09
Ventripoint Annual General Meeting 2021
JUN
10
Ventripoint Diagnostics Update and Q&A with George Adams, Alvira Macanovic and Dr. Mark Swaim
MAY
26
Ventripoint Diagnostics Update and Q&A with Dr. George Adams
FEB
11
Ventripoint CEO interviewed on TraderTV Live
Ventripoint CEO interviewed by Torrey Hills Capital
FEB
04
MAR
25
FEB
11
Ventripoint CEO interviewed by Torrey Hills Capital
FEB
04
MAY
13
BioPub/Torrey Hills Capital Zoom Webinar
Topic: Ventripoint: Bigger and Better, with CEO Dr. George Adams
APR
28
Ventripoint Diagnostics Update - Overview & Update on GE Health Collaboration
APR
25
Ventripoint Diagnostics Update
INVESTOR RELATIONS TEAM
Jonathan Robinson
Oak Hill Financial Inc.
(416) 669-1001
JRobinson@oakhillfinancial.ca